by Alison Kanski
NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.
Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more
by Anne Doerr
New findings by researchers at Yale Cancer Center demonstrate a novel strategy to treat tumor growth in breast and ovarian cancers characterized by HER2 gene amplification, an increase in the number of copies of a gene. Gene … Read more
Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with … Read more
A new advanced computing technique using routine medical scans to enable doctors to take fewer, more accurate tumour biopsies, has been developed by cancer researchers at the University of Cambridge. This is an important step towards precision tissue sampling for
By Caroline Hopkins
Using organoids that closely model certain features of ovarian tumors, researchers have identified and tested treatment combinations that may benefit patients, many of whom experience acquired or de novo resistance to PARP inhibitors.
In a study recently … Read more
By Angus Liu
Many oncology researchers and practitioners scrutinize genetic alterations in cancer, but they either focus on one particular tumor type or one mutation that occurs across tumors. A large-scale study focusing on precision medicine in cancer is now … Read more
Researchers have seen promising results by injecting dog and mouse tumors with the cowpea mosaic virus. Now they’re aiming for a human trial.
By Daniel Oberhaus
Researchers are optimistic that data from a first-in-human clinical trial of Bayer’s ATR-inhibiting agent, BAY-1895344, may pave the way for a new class of precision oncology treatments for patients with certain DNA damage response (DDR) defects in their tumors.
The … Read more
Precision oncology aims to use genetic features of a patient’s tumor to tailor anti-cancer therapy. DNA mutations in a drug target have provided a number of therapeutic opportunities; however, there are many cancer types that do not have obvious targetable … Read more
DNA shed by tumors into the bloodstream is starting to be used for the early detection of cancer and for monitoring how well treatment is working. Such DNA, which is called circulating tumor DNA (ctDNA), hasn’t been quite as helpful
… Read moreClearity’s Executive Director, Hillary Theakston, spoke on a panel of industry leaders at SXSW on ‘Frontiers of Cancer: Racing Toward A Cure’. Hillary, along with fellow panelists Amy Puliafito, Bobbie Rimel, MD, and Karl Handelsman discussed major investments, … Read more
Medical science has made tremendous advances in “personalized medicine” — drugs that fight cancer and other diseases by boosting the immune system or targeting specific genetic traits.
Former U.S. President Jimmy Carter benefited from one of these
… Read moreResearchers at Georgia Institute of Technology (Georgia Tech) have developed a new open-source decision support tool designed to help clinicians chose the chemotherapy drug best suited for individual patients.
The open-source support vector machine (SVM)-based algorithm predicted the chemotherapy drug … Read more
Proponents of precision medicine cite the growing numbers of successful precision cancer drugs. The examples of Herceptin (trastuzumab), Gleevec (imatinib mesylate), Xalkori (crizotinib), and Zelboraf (vemurafenib) come to mind. Skeptics, on the other hand, focus on the … Read more
New research has shown that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.
BRAF inhibitors block the activity of mutated BRAF gene. They are currently … Read more
Platinum/taxane combinations are the most effective regimens for treatment of epithelial ovarian cancer. Response varies between patients, but because the molecular basis for resistance is not defined, patients receive so-called one size fits all therapy. In contrast, elucidation of the … Read more
While precision medicine has been a modern go-to approach by physicians in various malignancies, it is demonstrating a particular benefit in ovarian cancer, especially using the method for clinical trial enrollment and in determining whether patients are eligible to receive … Read more
By: Laura L. Holman, MD, MS
We’ve come a long way in treating ovarian cancer. This treatment has historically consisted of debulking surgery for nearly every patient, but it is evolving to become more informed and precise. Diagnostic laparoscopy, for … Read more
